In line with the hypothesis that NMD might function as checkpoint of tumor antigenicity, we interrogated the scRNAseq dataset from the study [21] to see if higher expansion of T cells could be associated with SMG1 changes upon anti-PD-1 antibody treatment (Pembrolizumab). This evidence concerns the gene SMG1 and neoplasm.